Lyra Therapeutics, Inc.
LYRA
$0.73
-$0.01-1.22%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -74.05% | -59.21% | -57.69% | -29.46% | -1.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -74.05% | -59.21% | -57.69% | -29.46% | -1.54% |
| Cost of Revenue | -26.03% | -144.31% | -135.91% | -122.36% | -97.17% |
| Gross Profit | -449.43% | 146.91% | 138.53% | 125.36% | 100.37% |
| SG&A Expenses | -37.62% | -34.46% | -29.58% | -19.25% | -2.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -51.90% | -52.10% | -52.18% | -36.87% | -7.18% |
| Operating Income | 51.34% | 51.95% | 52.05% | 37.04% | 7.32% |
| Income Before Tax | 69.05% | 66.25% | 61.69% | -15.52% | -49.14% |
| Income Tax Expenses | -71.79% | -70.00% | -67.80% | -50.85% | -33.90% |
| Earnings from Continuing Operations | 69.05% | 66.25% | 61.70% | -15.47% | -49.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 69.05% | 66.25% | 61.70% | -15.47% | -49.07% |
| EBIT | 51.34% | 51.95% | 52.05% | 37.04% | 7.32% |
| EBITDA | 51.72% | 52.42% | 52.37% | 37.32% | 7.24% |
| EPS Basic | 73.09% | 68.58% | 64.79% | 6.28% | -3.52% |
| Normalized Basic EPS | 57.42% | 55.16% | 56.84% | 47.84% | 33.98% |
| EPS Diluted | 73.09% | 68.58% | 64.79% | 6.28% | -3.52% |
| Normalized Diluted EPS | 57.42% | 55.16% | 56.84% | 47.84% | 33.98% |
| Average Basic Shares Outstanding | 19.20% | 11.94% | 11.50% | 21.88% | 38.57% |
| Average Diluted Shares Outstanding | 19.20% | 11.94% | 11.50% | 21.88% | 38.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |